Ann: AstraZeneca to use new ResApp software in clinical study, page-77

However AStraZeneca using RAP will lend wieght tio the efficacy vs probablr risks. AZ wouldn't be using it if there were "probable risks"...I know it isn't quite the same as what FDA wrere referring to but hey...AZ do have a huge whack of pull. Counts for more than we may think moving forward, The patient (meaning several years IMHO) investors will be rewarded sometime down the track...the trick down the track is not to allow the downrampers to destroy the faith Keep the faith! Yep, I have been guilty of whinging of late but with stuff all news and no android idea we are simply hanging on in hope that the team are competent and not smudging the facts. Go RAP! On the face of it all we are slowly getting into shape.